OpenAPS, Seattle, WA, USA.
J Diabetes Sci Technol. 2022 Mar;16(2):500-503. doi: 10.1177/1932296820957360. Epub 2020 Sep 16.
Commercial automated insulin delivery (AID) systems are usually assessed based on clinical outcomes, ignoring uptake. A qualitative study evaluated user experiences when switching to currently available commercial AID. Interview feedback was coded on key themes including the adoption experience with regards to quality of life, clinical outcomes, and users' expectations. Most felt their learning curve was easy. Most saw reduced hypoglycemia and increased time in range, although there were outliers. Many mentioned post-meal hyperglycemia as an improvement area for commercial AID. Users with one particular continuous glucose monitor (CGM) type reported sleep disruption. Companies should consider real-world user feedback with regards to improving training materials for new users with less CGM experience and by improving target flexibility and postprandial algorithm performance, plus reducing manual interventions required by users.
商业自动化胰岛素输送（AID）系统通常基于临床结果进行评估，而忽略了采用情况。一项定性研究评估了用户在切换到当前可用的商业 AID 时的体验。采访反馈根据关键主题进行编码，包括生活质量、临床结果和用户期望方面的采用体验。大多数人认为他们的学习曲线很容易。大多数人认为低血糖减少，时间在目标范围内增加，尽管也有例外。许多人提到餐后高血糖是商业 AID 的一个改进领域。一些使用特定连续血糖监测仪（CGM）类型的用户报告说睡眠受到干扰。公司应该考虑实际用户的反馈，以改进针对 CGM 经验较少的新用户的培训材料，并改善目标灵活性和餐后算法性能，同时减少用户所需的手动干预。
